Radioresistance poses a significant challenge in the effective treatment of cervical cancer, often leading to poor patient outcomes. MicroRNA-21 (miR-21) and MicroRNA-145 (miR-145) are oncogenic micro-RNAs associated with various cancers, including cervical cancer, but their potential as predictive biomarkers for radioresistance remains underexplored. This study aimed to investigate the association between miR-21 and miR-145 expressions and the response to radiation therapy in cervical cancer patients. An analytical cross-sectional study was conducted on 140 subjects with cervical cancer stages IIIB and IVA who received definitive radiotherapy. miR-21 and miR-145 expressions were measured using real-time reverse transcriptase–polymerase chain reaction (RT-qPCR). A total of 102 subjects (72.9%) were classified as having stage III cervical cancer, and 38 subjects (27.1%) were classified as having stage IV cervical cancer. Disease progression occurred in 60.7% of subjects. The cut-off value for miR-21 expression was 0.00088 nmol/(mg/mL) (AUC 0.676, sensitivity 70.8%, specificity 50.8%), and a higher expression was significantly associated with radioresistance (p = 0.010). miR-145, with a cut-off of 0.0239 nmol/(mg/mL) (AUC 0.612, sensitivity 67.5%, specificity 45.5%), showed no significant association with treatment response (p = 0.132). Combining miR-21 and miR-145 (AUC 0.639, sensitivity 68.6%, specificity 46.9%, p = 0.063) did not significantly improve the predictive accuracy. This study suggests that an elevated miR-21 expression is significantly associated with radioresistance in cervical cancer patients, while miR-145 expression shows no significant correlation with treatment response. Additionally, combining miR-21 and miR-145 does not enhance the predictive power.

Objectives: This study aims to describe the ultrasound findings and biomarker profiles (CA-125, HE4, CEA, ADA, and IGRA) in confirmed cases of peritoneal tuberculosis (PTB) and to discuss their relevance in clinical evaluation. Methods: This is a retrospective study utilizing data from 12 female subjects with a confirmed PTB diagnosis at Cipto Mangunkusumo Hospital and Hermina Depok Hospital between 2018 and 2023. Data were extracted from medical records. Biomarker levels were measured using standardized assays in a single accredited laboratory. Ultrasonography was performed using the Mindray Resona 7 system. Results: The mean age was 33.0 ± 9.7 years. Ultrasonography identified significant features of PTB, such as hydrosalpinx 7 (58.3%), adhesions 6 (50%), ascites 7 (58.3%), cystic/mass-like lesions 4 (33.3%), and involvement of the rectosigmoid colon and small bowel 2 (16.6%). CA-125 levels were elevated (mean: 484.25 U/mL), and HE4 was high in 41.6% of cases (mean: 66.8 pmol/L). CEA levels remained low (mean: 1.725 ng/mL), and ADA levels were elevated in all patients (mean: 45.8 U/L). IGRA testing yielded a 75% positivity rate, with one patient converting from negative to positive after a month. Conclusions: Ultrasound remains a valuable imaging modality for identifying characteristic features of PTB, particularly hydrosalpinx and ascites. Elevated CA-125 and ADA, alongside IGRA results, may support clinical suspicion and help guide diagnosis in settings where invasive procedures are limited.

Cervical cancer is the fourth most prevalent cancer among women globally. Protein concentrations of Large Tumor Suppressor Kinase-1 (LATS1) and Nuclear Factor Kappa-B (NF-κB) have been identified as prospective biomarkers of radioresistance in cervical cancer. This preliminary study aimed to investigate the effectiveness of LATS1 and NF-κB levels as a biomarker for radioresistance and evaluate their response to radiation in cervical cancer patients. A comprehensive cross-sectional study was conducted involving 114 subjects diagnosed with advanced stages cervical cancer (stage IIIB and IVA) who underwent definitive radiotherapy. The concentrations of LATS1 and NF-κB were measured using ELISA from biopsy samples taken prior to the initiation of radiotherapy. This study’s finding included 114 subjects, with a median age of 53 years. A total of 85 (74.5%) subjects had stage IIIB, while 29 (25.4%) subjects had stage IVA. The cut-offs for LATS1 and NF-κB were 0.02765 ng/mg and 192.42 pg/mg, respectively. Subjects with a higher expression of LATS1 were found to be unresponsive to radiation therapy (p ≤ 0.001; AUC = 32.7%), and subjects with a lower expression of NF-κB were found to be unresponsive to radiation therapy (p = 0.009; AUC = 61%). This study suggests that elevated LATS1 expression may inversely predict radioresistance, while NF-κB expression shows a weak correlation with resistance to radiation therapy.